 |
市场调查报告书
商品编码
1402571
柳氮磺吡啶市场：依产品类型、依应用、依最终用户、按地区Sulfasalazine Market, By Product Type, By Application, By End User, By Geography |
||||||
柳氮磺吡啶的全球市场规模预计将从2023年的20.1亿美元成长到2030年的29.6亿美元，预测期内复合年增长率为5.7%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 20.1亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期复合年增长率 | 5.70% | 2030年市场规模预测 | 29.6亿美元 |
柳氮磺吡啶是一种药物，属于缓解疾病抗风湿药物 (DMARD)，主要用于治疗发炎性肠道疾病，如类风湿性关节炎、溃疡性大肠炎和克隆氏症。该药物以其磺胺吡啶和 5-胺基水杨酸 (5-ASA) 的独特组合而闻名，这两者都有助于提高其治疗功效。在类风湿性关节炎中，柳氮磺胺吡啶可抑制免疫系统反应，减少发炎，并减轻关节疼痛和肿胀。它通常被作为综合治疗计划的一部分来控制这种慢性自体自体免疫疾病的症状和进展。发炎性肠道疾病疾病涉及胃肠道的慢性发炎，柳氮磺吡啶的发炎特性可能有益于治疗与溃疡性大肠炎和克隆氏症相关的症状。柳氮磺吡啶的 5-ASA 成分被认为在胃肠道内的发炎作用中发挥重要作用。柳氮磺吡啶通常是口服给药，其效果通常需要一段时间才能显现。与任何药物一样，由于可能存在副作用，其使用受到医疗保健专业人员的密切监控。柳氮磺吡啶广泛用于治疗某些发炎疾病，由于其不同的作用机制，在这些疾病的医疗管理中仍然是一种有价值的治疗选择。
市场动态
柳氮磺吡啶市场的成长受到几个关键因素的影响。首先，全球自体自体免疫疾病和胃肠道疾病盛行率的上升是一个关键驱动因素。随着人们对这些疾病的认识和诊断的增加，对柳氮磺吡啶和类似药物的需求可能会增加。其次，人口高龄化，尤其是新兴市场的人口老化，正在促进市场扩张。老年人更容易患发炎疾病，增加了对柳氮磺吡啶等长期管理和治疗方案的需求。第三，製药业加大研发力道可能推出更先进、更有效的柳氮磺吡啶製剂，进一步推动市场成长。
然而，市场也可能面临挑战，例如替代治疗方法的可用性以及与柳氮磺吡啶相关的潜在副作用。医疗保健系统的监管变化和定价压力可能会影响市场动态。
本研究的主要特点
- 该报告对全球柳氮磺吡啶市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球柳氮磺吡啶市场的主要企业。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的资讯。
- 柳氮磺吡啶全球市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员可以透过用于分析全球柳氮磺吡啶市场的各种策略矩阵来促进决策。
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 提高认识和诊断
- 与先进治疗方法的竞争
- 联合治疗
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第四章全球柳氮磺吡啶市场－冠状病毒(COVID-19) 大流行的影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 供需面分析
- 经济影响
第五章全球柳氮磺吡啶市场，依产品类型，2018-2030
- 2023年及2030年市场占有率分析（%）
- 与前一年同期比较成长分析，2019-2030
- 细分市场趋势
- 非专利磺吡啶
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 柳氮磺吡啶品牌
- 2018-2030年市场规模及预测、与前一年同期比较成长率
第六章全球柳氮磺吡啶市场，依应用分类，2018-2030
- 2023年及2030年市场占有率分析（%）
- 与前一年同期比较成长分析，2019-2030
- 细分市场趋势
- 类风湿性关节炎
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 克隆氏症
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 溃疡性大肠炎
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 其他发炎性肠道疾病
- 2018-2030年市场规模及预测、与前一年同期比较成长率
第 7 章全球柳氮磺吡啶市场，依最终用户划分，2018-2030 年
- 2023年及2030年市场占有率分析（%）
- 与前一年同期比较成长分析，2019-2030
- 细分市场趋势
- 医院
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 诊所
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 门诊手术中心
- 2018-2030年市场规模及预测、与前一年同期比较成长率
- 其他（学术研究机构等）
- 2018-2030年市场规模及预测、与前一年同期比较成长率
第八章全球柳氮磺吡啶市场，按地区，2018-2030
- 2023 年和 2030 年按国家/地区分類的市场占有率分析 (%)
- 2019-2030与前一年同期比较成长分析（按国家）
- 各国的趋势
- 北美洲
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模及应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
- 美国
- 加拿大
- 拉丁美洲
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模及应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模及应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模及应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 中东
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模与应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030 年市场规模及各国预测、与前一年同期比较成长率
- GCC
- 以色列
- 其他中东地区
- 非洲
- 2018-2030 年市场规模与按产品类型预测、与前一年同期比较成长率
- 2018-2030 年市场规模及应用预测、与前一年同期比较成长率
- 2018-2030 年市场规模与最终用户预测、与前一年同期比较成长率
- 2018-2030年按国家/次区域分類的市场规模与预测、与前一年同期比较成长率
- 北非
- 中部非洲
- 南非
第9章竞争形势
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Dr. Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
第10章
- 调查方法
- 关于出版商
The global sulfasalazine market size is expected to grow from US$ 2.01 Bn in 2023 to US$ 2.96 Bn by 2030, at a CAGR of 5.7% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.01 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.70% | 2030 Value Projection: | US$ 2.96 Bn |
Sulfasalazine is a medication that falls under the category of disease-modifying antirheumatic drugs (DMARDs) and is primarily used in the treatment of inflammatory conditions, particularly rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The drug is known for its unique combination of sulfapyridine and 5-aminosalicylic acid (5-ASA), both of which contribute to its therapeutic effects. In the context of rheumatoid arthritis, sulfasalazine works by suppressing the immune system's response, mitigating inflammation, and helping to alleviate joint pain and swelling. It is often prescribed as part of a comprehensive treatment plan to manage the symptoms and progression of this chronic autoimmune disorder. Inflammatory bowel diseases involve chronic inflammation of the digestive tract, and sulfasalazine's anti-inflammatory properties are beneficial in treating symptoms associated with ulcerative colitis and Crohn's disease. The 5-ASA component of sulfasalazine is believed to play a key role in this anti-inflammatory action within the gastrointestinal tract. Sulfasalazine is typically administered orally, and its effectiveness often requires some time to become evident. Like any medication, it may have potential side effects, and its use is closely monitored by healthcare professionals. While widely used for specific inflammatory conditions, sulfasalazine's diverse mechanisms of action continue to make it a valuable therapeutic option in the medical management of these diseases.
Market Dynamics
The growth of the sulfasalazine market is influenced by several key factors. First, the rising incidence of autoimmune and gastrointestinal disorders globally is a significant driver. As awareness and diagnosis of these conditions increase, the demand for sulfasalazine and similar medications is likely to grow. Second, the aging population, particularly in developed countries, contributes to the expansion of the market. Older individuals are more susceptible to inflammatory diseases, increasing the need for long-term management and treatment options like sulfasalazine. Third, ongoing research and development in the pharmaceutical industry may lead to the introduction of more advanced and effective formulations of sulfasalazine, further propelling market growth.
However, the market may also face challenges, such as the availability of alternative treatment options and the potential for side effects associated with sulfasalazine. Regulatory changes and pricing pressures in healthcare systems can impact market dynamics.
Key features of the study:
- This report provides in-depth analysis of the global sulfasalazine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sulfasalazine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Ipca Laboratories Ltd, Novalab Healthcare, Dr. Reddy's Laboratories, Inc., Actus Healthcare, Medisoft Pharma, OVERSEAS HEALTH CARE, Astonea Labs Private Limited. and Fibovil Pharmaceuticals Pvt Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sulfasalazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sulfasalazine market
Detailed Segmentation:
- Sulfasalazine Market Segmentation, By Product Type:
- Generic Sulfasalazine
- Branded Sulfasalazine
- Sulfasalazine Market Segmentation, By Application:
- Rheumatoid Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Other Inflammatory Bowel Diseases
- Sulfasalazine Market Segmentation, By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others (Academic and Research Institutes etc.)
- Sulfasalazine Market Segmentation, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Top companies in Sulfasalazine Market
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
Table Of Content
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Global Sulfasalazine Market, By Product Type
- Market Global Sulfasalazine Market, By Application
- Market Global Sulfasalazine Market, By End user
- Market Global Sulfasalazine Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising awareness and diagnoses
- Competition from advanced therapies
- Combination therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Sulfasalazine Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Sulfasalazine Market , By Product Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Generic Sulfasalazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Branded Sulfasalazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Sulfasalazine Market , By Application, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Crohn's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Other Inflammatory Bowel Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
7. Global Sulfasalazine Market , By End User, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others (Academic and Research Institutes etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Sulfasalazine Market , By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Dr. Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
- Analyst Views
10. Section
- Research Methodology
- About us
